EP0349224A3
Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
Abstract
The present invention provides a compound having one of the formulae: Wherein: R₁ and R₆ may be the same or different and are H, alkyl or aralkyl having from 1 to 12 carbon atoms, provided that R₁ and R₆ are not H; R₇ is H, alkyl, aryl or aralkyl having from 1 to 12 carbon atoms; m is an integer from 3 to 6, inclusive; and n is an integer from 3 to 6, inclusive, or (IV), a salt thereof especially for anti-neoplastic, anti-psoriasis, anti-viral or anti-retroviral therapy or for controlling the growth of insects.

Term
Term ended
Projected expiry passed 23 June 2009, 17.3 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
1 sheet
Sheet 1
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| EP0162413A2 | Cites | European Patent Office (EPO) | X | Search report |
| EP0270349A2 | Cites | European Patent Office (EPO) | X | Search report |
| US4507321A | Cites | United States of America | X | Search report |
60 members in 8 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 210520 | United States of America | – | |
| 21052088 | United States of America | A | |
| 21052088 | United States of America | A | |
| US19880210520 | – | – | – |
Members60
| Document | Office | Kind | |
|---|---|---|---|
| EP0270349A2 | European Patent Office (EPO) | A2 | |
| JPS63211225A | Japan | A | |
| EP0349224A2 | European Patent Office (EPO) | A2 | |
| JPH02117647A | Japan | A | |
| EP0270349A3 | European Patent Office (EPO) | A3 | |
| EP0349224A3This record | European Patent Office (EPO) | A3 | |
| US5091576A | United States of America | A | |
| CA1305425C | Canada | C | |
| EP0536853A2 | European Patent Office (EPO) | A2 | |
| EP0536853A3 | European Patent Office (EPO) | A3 | |
| EP0270349B1 | European Patent Office (EPO) | B1 | |
| AT92466T | Austria | T | |
| DE3786896D1 | Germany | D1 | |
| DE3786896T2 | Germany | T2 | |
| JPH0653661B2 | Japan | B2 | |
| US5342945A | United States of America | A | |
| ES2059398T3 | Spain | T3 | |
| US5393757A | United States of America | A | |
| JPH07252193A | Japan | A | |
| US5455277A | United States of America | A | |
| US5462970A | United States of America | A | |
| EP0536853B1 | European Patent Office (EPO) | B1 | |
| AT136021T | Austria | T | |
| DE3751764D1 | Germany | D1 | |
| ES2088091T3 | Spain | T3 | |
| GR3020409T3 | Greece | T3 | |
| DE3751764T2 | Germany | T2 | |
| US5656671A | United States of America | A | |
| US5677351A | United States of America | A | |
| US5677352A | United States of America | A | |
| US5679682A | United States of America | A | |
| US5681837A | United States of America | A | |
| JP2673136B2 | Japan | B2 | |
| JP2748333B2 | Japan | B2 | |
| JPH10168067A | Japan | A | |
| US5827894A | United States of America | A | |
| US5866613A | United States of America | A | |
| US5886050A | United States of America | A | |
| JP2945360B2 | Japan | B2 | |
| CA1340773C | Canada | C | |
| US6034139A | United States of America | A | |
| US5866613B1 | United States of America | B1 | |
| US6147262A | United States of America | A | |
| US6184232B1 | United States of America | B1 | |
| US6262125B1 | United States of America | B1 | |
| US6342534B1 | United States of America | B1 | |
| US6362232B1 | United States of America | B1 | |
| US2002049256A1 | United States of America | A1 | |
| US2002094990A1 | United States of America | A1 | |
| US6455591B1 | United States of America | B1 | |
| US2002143068A1 | United States of America | A1 | |
| US6472426B2 | United States of America | B2 | |
| US2003100615A1 | United States of America | A1 | |
| USRE38417E | United States of America | E | |
| EP0349224B1 | European Patent Office (EPO) | B1 | |
| AT301993T | Austria | T | |
| DE68929539D1 | Germany | D1 | |
| ES2244953T3 | Spain | T3 | |
| DE68929539T2 | Germany | T2 | |
| US7094808B2 | United States of America | B2 |
67 legal events, as 5 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Nl: ceased due to reaching the maximum lifetime of a patentCeasedNLV7 | NLV7 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: patent expiredExpiredBE20 | BE20 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Fr: translation filedET | ET | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Definitive protectionFG2A | FG2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Ep patent validated in greeceEP | EP | GR | |
| Corresponds to:REF | REF | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| Designated contracting statesAK | AK | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0349224
- Publication, DOCDB
- 0349224
- Publication, EPODOC
- EP0349224
- Application
- 306425
- Application, DOCDB
- 89306425
- Application, EPODOC
- EP19890306425
Titles3
- English
- Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
- German
- Antineoplastische, antivirale oder antiretrovirale Sperminderivate
- French
- Dérivés de spermine ayant une activité antinéoplastique, antivirale ou antirétrovirale
Classification
- CPC, 18
- C07D239/04
- A01N33/04
- A01N43/54
- A61K31/13
- A61K31/131
- A61K31/135
- A61K31/505
- A61K31/506
- A61K31/785
- A61P17/00
- C07C209/08
- A61P31/00
- C07C209/62
- A61P31/04
- C07C211/14
- A61P31/12
- A61P33/06
- A61P35/00
- IPC, 21
- A01N33 04
- A01N33 12
- A01N43 54
- A61K31 00
- A61K31 13
- A61K31 131
- A61K31 135
- A61K31 505
- A61K31 506
- A61K31 785
- A61P17 00
- A61P31 00
- A61P31 04
- A61P31 12
- A61P35 00
- C07C209 08
- C07C209 62
- C07C211 14
- C07C211 27
- C07C211 53
- C07D239 04
Designated states13
- Contracting states, 13
- Austria
- Belgium
- Switzerland
- Germany
- Spain
- France
- United Kingdom
- Greece
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden